Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:
“Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients
– Study of 4,236 women with cN3b disease (2012–2021) from NCDB.
– SLNB rates increased from 8.5% (2012) to 35.1% (2021).
– nodal PCR was achieved in 24.9% of patients.
– No significant survival difference between SLNB and ALND in nPCR patients.
Axillary de-escalation strategies may be considered in well-selected cN3b patients with nPCR?”
Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients
Authors: Julia M. Selfridge, Zachary Schrank, Chris B. Agala, David W. Ollila, Kristalyn K. Gallagher, Dana L. Casey, Philip M. Spanheimer
